Ligand Pharmaceuticals Incorporated 13D and 13G filings for Viking Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-03-30 4:08 pm Sale |
2023-03-28 | 13D | Viking Therapeutics, Inc. VKTX |
LIGAND PHARMACEUTICALS INC LGND |
3,616,077 4.600% |
-2,449,003 (-40.38%) |
Filing |
| 2023-02-09 4:30 pm Sale |
2023-02-06 | 13D | Viking Therapeutics, Inc. VKTX |
LIGAND PHARMACEUTICALS INC LGND |
6,065,080 7.900% |
-1,274,303 (-17.36%) |
Filing |
| 2020-08-28 5:19 pm Sale |
2020-08-25 | 13D | Viking Therapeutics, Inc. VKTX |
LIGAND PHARMACEUTICALS INC LGND |
7,339,383 9.900% |
-218,700 (-2.89%) |
Filing |